BioProtein Technology BioPro+ Growth Factor Sublingual vs Renue by Science Liposomal NMN + NAD+ Patches
Specs, prices, editor verdict, and who should buy which - compared side-by-side.
BioProtein Technology BioPro+ Growth Factor Sublingual (premium, $250–$300/mo) vs Renue by Science Liposomal NMN + NAD+ Patches (premium, $89–$159/mo) - different tools for different jobs (see the per-product details below).
Compared on 2 shared specs · same category (supplement).
These are close picks. Both score in the same range. The right call depends on buyer profile - read the per-buyer recommendations below.
Side-by-side specs
| Spec | BioProtein Technology BioPro+ Growth Factor Sublingual | Renue by Science Liposomal NMN + NAD+ Patches |
|---|---|---|
| price | $250–$300/mo | $89–$159/mo |
| testing | Manufacturer QC; no third-party certification published | Third-party tested |
| cadence | Subscribe $249.98/mo or one-time $299.99 | Subscribe and save 10-15% |
BioProtein Technology BioPro+ Growth Factor Sublingual also publishes: format, serving, keyIngredient, guarantee
Renue by Science Liposomal NMN + NAD+ Patches also publishes: formats, dose, warranty
Who should buy which
Optimizers who want a legal, drug-free, needle-free alternative to prescription growth-hormone peptides, and who are comfortable paying a premium to run a try-it-and-track-how-you-feel experiment.
You want RCT-backed mechanisms. The human evidence that sublingual velvet-antler growth factors raise HGH or IGF-1 is weak, and IGF-1 oral bioavailability is questionable. At $249/mo, NAD precursors, creatine, and protein deliver far more proven value per dollar.
Buyers betting on NMN supplementation who want premium delivery formats (liposomal, sublingual, patch) and are willing to pay the engineering premium over commodity-tier oral capsules.
You haven't decided whether NMN is worth supplementing - start with the foundational stack (creatine, vit D, omega-3, magnesium). Or you're cost-anchored to the commodity tier - ProHealth and Tru Niagen are 50% cheaper.

